Florian Brand

Berlin, Germany

Florian Brand is the co-founder and Chief Executive Officer of ATAI Life Sciences. Florian also sits on the board of Compass Pathways, Perception Neuroscience, EtheogeniX Biosciences, GABA Therapeutics, and Innoplexus.

Atai cash purse down nearly half despite lower spending
Clinical-stage biopharmaceutical Atai Life Sciences (NASDAQ: ATAI) managed to lower spending during 2023, but still burned through much of the cash it had on hand....
Atai cash purse down nearly half despite lower spending Article
Mar 28, 2024
Atai nasal spray hits mark in depression study
Atai Life Sciences (NASDAQ: ATAI) released encouraging preliminary results from a Phase 2a study of its depression treatment drug, BPL-003. The company reported that a...
Atai nasal spray hits mark in depression study Article
Mar 27, 2024
Atai Makes $50 Million Investment Into Beckley Psytech
Psychedelic biotech company atai Life Sciences (NASDAQ: ATAI) announced a strategic investment in Beckley Psytech Limited, a private clinical-stage biotechnology company dedicated to transforming short-duration...
Atai Makes $50 Million Investment Into Beckley Psytech Article
Jan 04, 2024
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage...
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics Article
Jan 04, 2024
Atai Life Sciences Cuts Staffing by 30%, Extends Runway into 2026
Clinical-stage biopharmaceutical company Atai Life Sciences (Nasdaq: ATAI) provided investors and outlook on its operational runway as it begins to double down on trimming costs....
Atai Life Sciences Cuts Staffing by 30%, Extends Runway into 2026 Article
Mar 06, 2023
Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage Trial
Shares of Atai Life Sciences (Nasdaq: ATAI) plunged by more than 40% after phase 2a clinical trial results looking at ketamine therapy to treat depression...
Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage Trial Article
Jan 06, 2023
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
atai Life Sciences N.V., (NASDAQ: ATAI), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of...
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer Article
Dec 13, 2022

Last updated: Apr 16, 2021
Request Deletion